CoChat

Challenges of repurposing tetracyclines for the treatment of Alzheimer’s and Parkinson’s disease

Markulin, Iva, Matasin, Marija, Turk, Viktorija Erdeljic, Salković-Petrisic, Melita · 2022 · Journal of Neural Transmission

The DOI matches its Crossref record; 261 of the 261 references it cites were found in a registry or an index.

Abstract

The novel antibiotic-exploiting strategy in the treatment of Alzheimer's (AD) and Parkinson's (PD) disease has emerged as a potential breakthrough in the field. The research in animal AD/PD models provided evidence on the antiamyloidogenic, anti-inflammatory, antioxidant and antiapoptotic activity of tetracyclines, associated with cognitive improvement. The neuroprotective effects of minocycline and doxycycline in animals initiated investigation of their clinical efficacy in AD and PD patients which led to inconclusive results and additionally to insufficient safety data on a long-standing doxycycline and minocycline therapy in these patient populations. The safety issues should be considered in two levels; in AD/PD patients (particularly antibiotic-induced alteration of gut microbiota and its consequences), and as a world-wide threat of development of bacterial resistance to these antibiotics posed by a fact that AD and PD are widespread incurable diseases which require daily administered long-lasting antibiotic therapy. Recently proposed subantimicrobial doxycycline doses should be thoroughly explored for their effectiveness and long-term safety especially in AD/PD populations. Keeping in mind the antibacterial activity-related far-reaching undesirable effects both for the patients and globally, further work on repurposing these drugs for a long-standing therapy of AD/PD should consider the chemically modified tetracycline compounds tailored to lack antimicrobial but retain (or introduce) other activities effective against the AD/PD pathology. This strategy might reduce the risk of long-term therapy-related adverse effects (particularly gut-related ones) and development of bacterial resistance toward the tetracycline antibiotic agents but the therapeutic potential and desirable safety profile of such compounds in AD/PD patients need to be confirmed.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00702-021-02457-2

Cites

261 of 261 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Research works printed but not linked: 8

  1. Beauduy CEWL (2018) Tetracyclines, macrolides, clindamycin, chloramphenicol, streptogramins, & oxazolidinones. In: Katzung BG (ed) Basic and clinical pharmacology, 14th edn. McGraw Hill-Education, New York, pp 815–825
  2. Erekat NS (2018) Apoptosis and its role in Parkinson’s disease. In: Stoker TB, Greenland JC (eds) Parkinson’s disease: pathogenesis and clinical aspects, chapter 4. Codon Publications, Brisbane
  3. Forloni G, Salmona M, Marcon G et al (2012) Tetracyclines and prion infectivity. Infect Disord Drug Targets 9(1):23–30. https://doi.org/10.2174/1871526510909010023 · DOI · Paper page
  4. Holmes C (2017) Inflammation in Alzheimer’s disease. In: Ames D, O’Brien JT, Burns A (eds) Dementia, 5th edn. CRC Press, Boca Raton
  5. Ian C, Marilyn R (2001) Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65(3):232–260. https://doi.org/10.1128/MMBR.65.2.232 · doi:10.1128/mmbr.65.2.232
  6. Kempuraj D, Thangavel R, Natteru PA et al (2016) Neuroinflammation induces neurodegeneration. J Neurol Neurosurg Spine 1(1):1003
  7. Perdue BE, Standiford HC (1999) Tetracyclines. In: Yu VL, Merigan TC, Barriere SL (eds) Antimicrobial therapy and Vaccines. Williams and Wilkins, Baltimore, p 981
  8. Tong M, Dong M, De La Monte SM (2009) Brain Insulin-like growth factor and neurotrophin resistance in parkinson’s disease and dementia with Lewy bodies: potential role of manganese neurotoxicity. J Alzheimers Dis 16(3):585–599. https://doi.org/10.3233/JAD-2009-0995.Brain · doi:10.3233/jad-2009-0995.brain

Cited by

See all 36

Metadata

Authors
Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M.
Affiliations
University Hospital Centre Zagreb (HR)
Venue
Journal of Neural Transmission
Published
2022-01-04
Volume
129
Issue
5-6
Pages
773-804
ISSN
  • 0300-9564 (ISSN-L)
  • 1435-1463
OpenAlex
W4205398889
Cited by
36
References
261
Citations by year
2026: 5 · 2025: 13 · 2024: 7 · 2023: 7 · 2022: 4
FWCI
1.07
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Journal of Neural Transmission (publishedVersion)
  • PubMed (publishedVersion)
Funders
European Regional Development Fund (GA KK01.1.1.01.0007)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
tetracycline, drug repurposing, Alzheimer's disease, Parkinson's disease, minocycline, doxycycline, antibiotic resistance, gut microbiota, neuroprotection, chemically modified tetracyclines
MeSH terms
Alzheimer Disease, Animals, Anti-Bacterial Agents, Doxycycline, Humans, Minocycline, Parkinson Disease, Tetracycline, Drug Repositioning

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.